Abstract: The present invention relates to a polypeptide that is capable of promoting the covalent conjugation of two peptide tags or linkers and in particular to a polypeptide comprising: a) an amino acid sequence as set forth in SEQ ID NO: 1; or b) an amino acid sequence with at least 80% sequence identity to a sequence as set forth in SEQ ID NO: 1, wherein said amino acid sequence comprises a glutamic acid at position 61 and one or more of the following: 1) proline at position 66; 2) proline at position 95; 3) glycine at position 96; and 4) valine at position 97, wherein the specified amino acid residues are at positions equivalent to the positions in SEQ ID NO: 1 and wherein said polypeptide is capable of promoting the formation of an isopeptide bond between the lysine residue at position 9 of SEQ ID NO: 2 and the asparagine residue at position 17 of SEQ ID NO: 3.

Abstract: The present invention provides a method for producing rubber particles bound to a membrane-associated protein by cell-free protein synthesis. The present invention relates to a method for producing rubber particles bound to a membrane-associated protein, the method including the step of performing protein synthesis in the presence of both rubber particles and a cell-free protein synthesis solution containing an mRNA coding for a membrane-associated protein to bind the membrane-associated protein to the rubber particles.

Abstract: The Present invention relates to molecules isolated from the nucleic acid that encodes spider web proteins or fragments of these or other derivatives of these. The invention also refers to a chimerical gene and an expression vector containing molecules isolated from the nucleic acid that codes for proteins related to the webs of Nephilengys, cruentata, Avicularia juruensis and Parawixia bistriata spiders. Another embodiment of the present invention are transformed cells containing a chimerical gene or an expression vector of the present invention. Yet another embodiment of the present invention relates to a method for obtaining genetically modified organisms containing inventive chimerical genes or expression vectors and a method for obtaining recombinant proteins from the silks of Nephilengys, cruentata, Avicularia juruensis and Parawixia bistriata spiders. Finally, the invention describes products, such as biofilaments and compositions, using the recombinant proteins of the present invention.

Abstract: Methods for treating and preventing neurodegenerative disease, neurological injury, including stroke, via administration of Transient receptor potential M2 (TRPM2)-inhibitors. The inhibitors may be administered in conjunction with another therapeutic agent or therapeutic regimen. The peptides may be administered to a human male. The peptides may be administered within eight hours of a neurological injury, such as a stroke.

Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Abstract: The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n?2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.

Abstract: This disclosure relates to recombinant proteins, vectors, and methods of treating neurological conditions by exposing neurons to an opsin and luciferase in the presence of a luciferin. In certain embodiments, the disclosure relates to treating or preventing epilepsy or seizures comprising administering an effective amount of a vector that encodes an opsin and luciferase in combination with a luciferin to a subject in need thereof.

Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tmor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The invention provides a method for separating a Factor VIII (FVIII) protein from a first composition comprising the FVIII protein, which contains at least the light chain of FVIII, and a von-Willebrand-Factor (vWF) protein which comprises at least the FVIII binding domain of vWF, wherein the FVIII protein can form a complex with the vWF protein, the method comprising the steps: contacting the first composition with an affinity resin comprising a ligand and a matrix, wherein the ligand has an affinity to the light chain of FVIII, and separating the affinity resin from the mixture to obtain a modified first composition and a second composition, wherein the second composition contains the affinity resin, and a complex of the FVIII protein and the vWF protein.

Abstract: A2M polypeptide compositions containing a non-natural bait region are disclosed. Methods of producing wild-type and variant A2M polypeptides and polynucleotides containing a non-natural bait region are also disclosed. The bait regions of the variant A2M polypeptides demonstrate enhanced protease inhibitory characteristics compared to wild-type A2M. Variant A2M polypeptides that demonstrate longer half-lives upon administration to an organism compared to wild-type A2M are disclosed. The A2M compositions are useful in treating a number of diseases and conditions including inflammation, chronic wounds, and diseases with a pathology associated with proteases.

Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.

Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.

Abstract: An anti-AGE antibody comprises a protein or peptide that comprises at least one amino acid sequence having at least 90% sequence identity, preferably at least 95% sequence identity, more preferably at least 98% sequence identity, with specific amino acid sequences. The anti-AGE antibody binds to a protein or peptide that exhibits a carboxymethyllysine modification. The anti-AGE antibody may be used for killing senescent cells, killing partially-functional or non-functional cells, treating sarcopenia, promoting tissue or organ regeneration, promoting regenerative processes or overcoming aging effects, treating atherosclerosis, preventing or delaying the onset of cataracts, preventing or delaying the onset of loss of adipose tissue, increasing health span, preventing or delaying the onset of lordokyphosis, treating inflammation or autoimmune disorders, treating neurodegenerative disorders or treating cancer.

Abstract: The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.

Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.

Abstract: Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.

Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.

Abstract: Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.

Abstract: The present invention provides for a humanized anti-BAG3 antibody or a fragment thereof, pharmaceutical compositions comprising said antibody and its use as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic, cardiovascular and/or degenerative nature.

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Abstract: Provided herein are compositions and methods related to conditioning a subject for a hematopoietic stem cell (HSC) transplantation using an inhibitor of a stem cell growth factor receptor (KIT). The compositions and methods described herein are particularly useful for a subject who is in need of a HSC transplantation and who is hypersensitive to at least one DNA damaging agent, e.g., a subject with fanconi anemia. Compositions and methods related to conditioning a fanconi anemia subject for HSC transplantation using an inhibitor of KIT are also provided herein.

Abstract: Provided herein are anti-PD-L1 antibodies and antigen-binding fragments thereof. Also provided are nucleic acids encoding the antibodies, compositions containing the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, infectious diseases and autoimmune diseases.

Abstract: Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.

Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.

Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.

Abstract: The present invention is directed to novel heterodimeric antibodies.

Abstract: The invention concerns a process for the manufacture of an acylated polysaccharide which comprises. (a) reacting a polysaccharide with an acylating agent to produce an acylated polysaccharide and (b) washing the acylated polysaccharide with water containing from 0.05 to 15 mg/l Ca2+-ions (c) recovering the washed acylated polysaccharide and an aqueous phase containing carboxylic acid from step (b).

Abstract: This invention relates to new destructured starch derivatives and elastomer compositions containing them. In particular this invention relates to destructured starch silyl ethers in which at least one oxygen atom of the destructured starch is covalently bonded to at least one silicon atom and/or to at least one compound containing silicon.

Abstract: The present invention provides a novel sulfated polysaccharide having anticoagulant activity. Specifically, the present invention provides a polysaccharide that includes a repetitive structure of a disaccharide unit composed of a hexuronic acid (HexA) residue and a ?-D-glucosamine (GlcN) residue and having 13% or higher of a 3-O-sulfation rate in GlcN residues.

Abstract: In a prior art reactor set up dense aggregates of microorganisms are formed, typically in or embedded in an extra cellular matrix. Such may relate to granules, to sphere like entities having a higher viscosity than water, globules, a biofilm, etc. The dense aggregates comprise extracellular polymeric substances, or biopolymers, in particular linear polysaccharides, The present invention is in the field of extraction a biopolymer from a granular sludge, a fibrous biopolymer obtained by said process, in particular alginate or bacterial alginate, and a use of said biopolymer.

Abstract: A tire manufacturing method includes making a master batch, using the master batch to make a rubber composition, and making a green tire. The master batch is made wherein a carbon-black-containing pre-coagulation rubber latex is coagulated to obtain a coagulum; a compound according to Formula (I) is added to the water-containing coagulum; wherein R1 and R2 each indicates a hydrogen atom, an alkyl group having 1 to 20 carbons, an alkenyl group having 1 to 20 carbons, or an alkynyl group having 1 to 20 carbons, R1 and R2 may be the same or different, and M+ indicates sodium ion, potassium ion, or lithium ion; and the compound according to Formula (I) is dispersed within the coagulum. The green tire is provided with unvulcanized rubber sheeting made up of the rubber composition, chafer(s), carcass ply or plies, and bead filler(s).

Abstract: The present disclosure provides a modified polymethylhydrosiloxane, a modified high-cis conjugated diene polymer, and a manufacturing method for the same, and a rubber composition and a tire using the same. The manufacturing method for the modified high-cis conjugated diene polymer comprises: performing a polymerization reaction to form a high-cis conjugated diene polymer; and making the high-cis conjugated diene polymer react with a first modifier, and then react with a condensation accelerator and a second modifier to generate a modified high-cis conjugated diene polymer; wherein the modified high-cis conjugated diene polymer has over 97% of cis-1,4 structure. The second modifier comprises a compound represented by the following formula (1).

Abstract: A core-shell copolymer includes a core including an emulsifying initiator-derived layer derived from an emulsifying initiator, and a core forming monomer-derived repeating unit, bound to the emulsifying initiator-derived layer; and a shell including a shell forming monomer-derived repeating unit, wherein the emulsifying initiator comprising a surfactant part, an initiator part, and a vinyl monomer-derived repeating unit, the surfactant part including an organic acid-based monomer-derived repeating unit, and the initiator part including a peroxide-based monomer-derived repeating unit, wherein the emulsifying initiator has a weight average molecular weight less than 250,000 g/mol.

Abstract: A polymer and methods of producing the polymer for use, for instance, in mineral processing, including kaolin and calcium carbonate beneficiation are discussed. The method of producing the polymer can include polymerizing at least one monomer in the presence of a polymerization initiator, a chain transfer agent, and a polymerization stabilizer to produce a polymer containing at least one carboxylic acid, wherein the at least one monomer includes an unsaturated carboxylic acid monomer, and wherein the polymer containing at least one carboxylic acid is stable and has a molecular weight of about 1000 g/mol to about 10,000 g/mol.

Abstract: Provided are a novel metallocene-supported catalyst and a method of preparing a polyolefin using the same. The metallocene-supported catalyst according to the present disclosure may be used in the preparation of polyolefins, it may have excellent activity and excellent reactivity with comonomers, and it may prepare olefinic polymers having a high molecular weight and a low molecular weight.

Abstract: The present disclosure relates to asymmetric ansa-metallocene catalyst compounds that include at least one indenyl ligand substituted at the 3-position with a C3-C40 ?-branched alkyl, such as 1-methylethyl, 1-methylpropyl, 1-methylbutyl, 1-ethylbutyl, 1,3-dimethylbutyl, 1-methyl-1-ethylbutyl, 1,1-diethylbutyl, 1-propylpentyl, and the like. Catalyst systems prepared with the catalyst compounds, polymerization methods using such catalyst systems, and polyolefins made using the polymerization methods are also described.

Abstract: A method comprising contacting a silica support with a titanium-containing solution to form a titanated silica support, wherein the titanium-containing solution comprises a titanium compound, a solvent, and a surfactant.

Abstract: The invention involves functionalizing polymeric beads, such as DVB beads, to add an epoxide or aldehyde group. The resulting beads are useful in various applications.

Abstract: The invention is related to a process for producing modified polyethylene having decreased melt flow rate (5 kg, 190° C.) (MFR). In particular, the present invention is directed to a process in a controlled manner for producing modified polyethylene recyclates having low MFR and low gel content directly by reactive extrusion processing.

Abstract: The present invention relates to a polypropylene having excellent stiffness and achieving energy reduction during foaming.

Abstract: The present invention provides a method for preparing a vinyl chloride-based polymer and a vinyl chloride-based polymer prepared thereby, the method comprising a step for performing suspension polymerization of a monomer for preparing a vinyl chloride-based polymer in the presence of a polymerization initiator, a dispersant, and water soluble cellulose ether, wherein the dispersant includes a mixture of two or more kinds of polyvinyl alcohol having different degrees of saponification, and the mole average degree of saponification of the polyvinyl mixture is from 76 mol % to 80 mol %, and the water soluble cellulose ether has a gel point of 60° C. to 90° C. and is added before the initiation of polymerization or at a time in which the polymerization conversion rate is 70% or less.

Abstract: This invention generally relates to a method for modulating interfacial wettability of a noncovalent nanoscopic monolayer or thin film. Particularly, this invention relates to a method for modulating interfacial wettability of a two-dimensional (2D) material using a molecular layer prepared from a polymerizable amphiphilic monomer having a hydrophilic head and a hydrophobic tail, wherein enhanced or decreased wettability of said 2D material is achieved by proper allocating the position of polymerizable group relative to the hydrophilic head and the hydrophobic tail.

Abstract: A copolymer of ethylene with silane groups containing comonomer that is produced in a high pressure radical polymerisation process comprising the steps of: (a) compressing ethylene together with the silane groups containing comonomer under pressure in a compressor, wherein a compressor lubricant is used for lubrication, (b) polymerising ethylene together with the silane groups containing comonomer in a polymerisation zone, (c) separating the obtained ethylene from the unreacted products and recovering the separated ethylene copolymer in a recovery zone, wherein in step a) the compressor lubricant comprises a mineral oil and ethylene copolymer has a silane groups containing comonomer content of 0.5 to 3 wt % and an MFR2 of 0.3 to 10 g/10 min. The copolymer of ethylene with silane groups containing comonomer can be used.

Abstract: The invention relates to an efficient process for the preparation and isolation of rubber particles formed in aqueous media and highly pure rubbers obtained thereby. The invention further relates to copolymer products comprising the same or derived therefrom.

Abstract: A prepolymerized resin and a method of preparing the prepolymerized resin are provided, the method comprising a step of prepolymerizing t-butyl styrene and unsaturated bond-containing polyphenylene oxide. The unsaturated bond-containing polyphenylene oxide comprises: methacrylate-terminated polyphenylene oxide, vinylbenzyl-terminated polyphenylene oxide, vinylbenzyl-modified bisphenol A polyphenylene oxide resin, vinyl-containing chain-extended polyphenylene oxide resin or a combination thereof. A resin composition comprising the prepolymerized resin and an article made from the resin composition are also provided.